Orlistat Resensitizes Sorafenib-Resistance in Hepatocellular Carcinoma Cells through Modulating Metabolism.

Shueng, Pei-Wei; Chan, Hui-Wen; Lin, Wei-Chan; Kuo, Deng-Yu; Chuang, Hui-Yen

Shueng, Pei-Wei; Chan, Hui-Wen; Lin, Wei-Chan; Kuo, Deng-Yu; Chuang, Hui-Yen.

Afiliação

Shueng PW; Division of Radiation Oncology, Department of Radiology, Far Eastern Memorial Hospital, New Taipei City 220, Taiwan.
Chan HW; Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei City 112, Taiwan.
Lin WC; Department of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University, Taipei City 112, Taiwan.
Kuo DY; Department of Radiology, Cathay General Hospital, Taipei City 106, Taiwan.
Chuang HY; School of Medicine, Fu-Jen Catholic University, New Taipei City 242, Taiwan.

Int J Mol Sci ; 23(12)2022 Jun 10.

Article em En | MEDLINE | ID: mdl-35742944

Assuntos

Antineoplásicos; Carcinoma Hepatocelular; Neoplasias Hepáticas; Antineoplásicos/farmacologia; Antineoplásicos/uso terapêutico; Carcinoma Hepatocelular/metabolismo; Linhagem Celular Tumoral; Proliferação de Células; Resistencia a Medicamentos Antineoplásicos; Ácidos Graxos/farmacologia; Fluordesoxiglucose F18/uso terapêutico; Glucose/farmacologia; Humanos; Neoplasias Hepáticas/metabolismo; Orlistate/farmacologia; Orlistate/uso terapêutico; Sorafenibe/farmacologia; Sorafenibe/uso terapêutico

Palavras-chave

fatty acid synthase; hepatocellular carcinoma; metabolism; sorafenib resistance

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas / Antineoplásicos Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google